Skip to Main Content
Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 2024, Issue 1
December 6 2024
Issue Cover
In this Issue

Table of Contents

Ham-Wasserman Lecture

Sickle cell disease in India: the journey and hope for the future
Kalpna Gupta,Lakshmanan Krishnamurti,Dipty Jain
View Articletitled, Sickle cell disease in India: the journey and hope for the future

A Little Less Conversation, a Little More Action: An Outcome Equity Roadmap for Children and AYAs With Leukemia and Lymphoma

The lasting impact of the ACA: how Medicaid expansion reduces outcome disparities in AYAs with leukemia and lymphoma
Xin Hu,Sharon M. Castellino,Xu Ji
View Articletitled, The lasting impact of the ACA: how Medicaid expansion reduces outcome disparities in AYAs with leukemia and lymphoma
Targeting hardship: poverty as a modifiable risk factor in childhood leukemia and lymphoma treatment
Puja J. Umaretiya,Rahela Aziz-Bose,Colleen Kelly,Kira Bona
View Articletitled, Targeting hardship: poverty as a modifiable risk factor in childhood leukemia and lymphoma treatment
Sharing is caring: a network collaborative approach to identify and address barriers in accessing clinical trials in adolescents and young adults with leukemia and lymphoma
Caroline Hesko,Jessica Heath,Michael E. Roth,Nupur Mittal
View Articletitled, Sharing is caring: a network collaborative approach to identify and address barriers in accessing clinical trials in adolescents and young adults with leukemia and lymphoma

A Shifting Landscape: Treatment of MCL

Your chemo is no good here: management of high-risk MCL
Yazeed Sawalha,Kami Maddocks
View Articletitled, Your chemo is no good here: management of high-risk MCL
To consolidate or not to consolidate: the role of autologous stem cell transplantation in MCL
E. Silkenstedt,M. Dreyling
View Articletitled, To consolidate or not to consolidate: the role of autologous stem cell transplantation in MCL
T-cell–based therapies for treating relapsed or refractory mantle cell lymphoma
Zachary D. Epstein-Peterson,M. Lia Palomba
View Articletitled, T-cell–based therapies for treating relapsed or refractory mantle cell lymphoma

Addressing Unmet Needs In T-Cell Lymphomas

BV and beyond: how to incorporate novel agents into PTCL management
Imran A. Nizamuddin,Neha Mehta-Shah
View Articletitled, BV and beyond: how to incorporate novel agents into PTCL management
Through thick and thin: confronting the aggressive cutaneous T-cell lymphomas
Robert Stuver,Steven M. Horwitz
View Articletitled, Through thick and thin: confronting the aggressive cutaneous T-cell lymphomas
The role of stem cell transplant (auto and allo) in PTCL and CTCL
Peter Dreger,Norbert Schmitz
View Articletitled, The role of stem cell transplant (auto and allo) in PTCL and CTCL

Adult ALL Advancements: Optimizing Cure in 2024

Ph+ ALL: new approaches for upfront therapy
Marlise R. Luskin
View Articletitled, Ph+ ALL: new approaches for upfront therapy
Ph− ALL: immunotherapy in upfront treatment
Matthias Stelljes
View Articletitled, Ph− ALL: immunotherapy in upfront treatment
Transplant in ALL: who, when, and how?
Curtis Marcoux,Partow Kebriaei
View Articletitled, Transplant in ALL: who, when, and how?

Adult CAR-T Outcomes: Beyond the Acronyms (OS, PFS, CRS, ICANS)

Patient-reported outcomes after CAR T-cell therapy in patients with hematological malignancies
Xin Shelley Wang,Samer A. Srour
View Articletitled, Patient-reported outcomes after CAR T-cell therapy in patients with hematological malignancies
Late complications and long-term care of adult CAR T-cell patients
Michael R. Bishop
View Articletitled, Late complications and long-term care of adult CAR T-cell patients
Mitigating and managing infection risk in adults treated with CAR T-cell therapy
Nadeem Tabbara,M. Veronica Dioverti-Prono,Tania Jain
View Articletitled, Mitigating and managing infection risk in adults treated with CAR T-cell therapy

ALPS, CVID, and LGL: When Autoimmune Cytopenias are a Marker of Underlying Immune Disease

Professional illustration by Patrick Lane, ScEYEnce Studios

Beyond FAScinating: advances in diagnosis and management of autoimmune lymphoproliferative syndrome and activated PI3 kinase δ syndrome
V. Koneti Rao,Stefania Pittaluga,Gulbu Uzel
View Articletitled, Beyond FAScinating: advances in diagnosis and management of autoimmune lymphoproliferative syndrome and activated PI3 kinase δ syndrome
Common variable immunodeficiency: autoimmune cytopenias and advances in molecular diagnosis
Charlotte Cunningham-Rundles,Jean-Laurent Casanova,Bertrand Boisson
View Articletitled, Common variable immunodeficiency: autoimmune cytopenias and advances in molecular diagnosis
Large granular lymphocyte leukemia: a clonal disorder with autoimmune manifestations
Tony Marchand,Cédric Pastoret,Aline Moignet,Mikael Roussel,Thierry Lamy
View Articletitled, Large granular lymphocyte leukemia: a clonal disorder with autoimmune manifestations

AML M&Ms: How to Integrate Mutations and MRD Data

Mutations and MRD: clinical implications of clonal ontogeny
Jerald Radich
View Articletitled, Mutations and MRD: clinical implications of clonal ontogeny
Mutation- and MRD-informed treatment decisions for the transplant-eligible AML patient
Michael Heuser,Rabia Shahswar
View Articletitled, Mutation- and MRD-informed treatment decisions for the transplant-eligible AML patient
Mutation- and MRD-informed treatments for transplant-ineligible patients
Curtis A. Lachowiez,Courtney D. DiNardo
View Articletitled, Mutation- and MRD-informed treatments for transplant-ineligible patients

Anticoagulation SOS: Navigating Monitoring Conundrums

DOACs: role of anti-Xa and drug level monitoring
Siraj Mithoowani,Deborah Siegal
View Articletitled, DOACs: role of anti-Xa and drug level monitoring
Troubleshooting heparin resistance
Cheryl L. Maier,Jean M. Connors,Jerrold H. Levy
View Articletitled, Troubleshooting heparin resistance
Warfarin and heparin monitoring in antiphospholipid syndrome
Prabal Mittal,Zara Sayar,Hannah Cohen
View Articletitled, Warfarin and heparin monitoring in antiphospholipid syndrome

Beyond TTP: “Atypical” TMAs for the Hematologist

Atypical hemolytic uremic syndrome: diagnosis, management, and discontinuation of therapy
Anuja Java
View Articletitled, Atypical hemolytic uremic syndrome: diagnosis, management, and discontinuation of therapy
Transplant-associated TMA: the conundrum of diagnosis and treatment
Ang Li,Sarah E. Sartain
View Articletitled, Transplant-associated TMA: the conundrum of diagnosis and treatment
Catastrophic antiphospholipid syndrome: a CAPS-tivating hematologic disease
Brittany M. Salter,Mark Andrew Crowther
View Articletitled, Catastrophic antiphospholipid syndrome: a CAPS-tivating hematologic disease
New definitions for antiphospholipid syndrome: ready for clinical use?
Evidence-Based Minireview
Andrew B. Song,Rebecca K. Leaf
View Articletitled, New definitions for antiphospholipid syndrome: ready for clinical use?

Challenges and Opportunities of Sickle Cell Care in Africa

Newborn screening initiatives for sickle cell disease in Africa
Obiageli E. Nnodu,Chinwe Onyinye Okeke,Hezekiah Alkali Isa
View Articletitled, Newborn screening initiatives for sickle cell disease in Africa
Transfusions, disease-modifying treatments, and curative therapies for sickle cell anemia in Africa: where are we now?
Isaac Odame,Godwin Nosakhare Bazuaye
View Articletitled, Transfusions, disease-modifying treatments, and curative therapies for sickle cell anemia in Africa: where are we now?
The intersection of sickle cell disease, stigma, and pain in Africa
Kofi A. Anie
View Articletitled, The intersection of sickle cell disease, stigma, and pain in Africa

Challenges In Cancer-Associated Thrombosis

Management of anticoagulation in patients with brain metastasis
Eva. N. Hamulyák,Shlomit Yust-Katz,Avi Leader
View Articletitled, Management of anticoagulation in patients with brain metastasis
Trousseau syndrome: management of refractory VTE
Jeffrey I. Zwicker
View Articletitled, Trousseau syndrome: management of refractory VTE
Treatment of VTE in the thrombocytopenic cancer patient
Florian Moik,Cihan Ay
View Articletitled, Treatment of VTE in the thrombocytopenic cancer patient
Supplemental data

Chasing Zebras: Navigating Rare Myeloid Neoplasms

The spectrum of Ph-negative disease: CNL and CSF3R-related disorders
Robert P. Hasserjian
View Articletitled, The spectrum of Ph-negative disease: CNL and <em>CSF3R</em>-related disorders
BPDCN: state of the art
Naveen Pemmaraju
View Articletitled, BPDCN: state of the art
How to think about acute leukemia of ambiguous lineage
Olga K. Weinberg
View Articletitled, How to think about acute leukemia of ambiguous lineage

Follicular Lymphoma: Playing the Long Game

In pursuit of a functional cure for follicular lymphoma
Judith Trotman,Janlyn Falconer
View Articletitled, In pursuit of a functional cure for follicular lymphoma
The POD24 challenge: where do we go from here for early progressors?
Patrizia Mondello,Carla Casulo
View Articletitled, The POD24 challenge: where do we go from here for early progressors?
Sequencing bispecific antibodies and CAR T cells for FL
David A. Russler-Germain,Nancy L. Bartlett
View Articletitled, Sequencing bispecific antibodies and CAR T cells for FL
Predicting bispecific antibody failure in diffuse large B-cell lymphoma
Evidence-Based Minireview
Allison Barraclough,Eliza A. Hawkes
View Articletitled, Predicting bispecific antibody failure in diffuse large B-cell lymphoma

Handling Bad News: How to Best Manage TP53 Myeloid Disease

Are TP53 mutations all alike?
Terrence N. Wong,Daniel C. Link
View Articletitled, Are <em>TP53</em> mutations all alike?
Nontransplant treatment approaches for myeloid neoplasm with mutated TP53
Ansh K. Mehta,Marina Konopleva
View Articletitled, Nontransplant treatment approaches for myeloid neoplasm with mutated TP53
Transplant options and outcomes for TP53 myeloid disease
Hugo F. Fernández,Asmita Mishra
View Articletitled, Transplant options and outcomes for <em>TP53</em> myeloid disease

Hematologic Challenges at the End of Life

Challenges in hospice and end-of-life care in the transfusion-dependent patient
Rachel Rodenbach,Thomas Caprio,Kah Poh Loh
View Articletitled, Challenges in hospice and end-of-life care in the transfusion-dependent patient
Anticoagulation at the end of life: whether, when, and how to treat
Anna L. Parks
View Articletitled, Anticoagulation at the end of life: whether, when, and how to treat
End-of-life care for people with sickle cell disease: barriers to and facilitators of high-quality care
Rushil V. Patel,Emily E. Johnston
View Articletitled, End-of-life care for people with sickle cell disease: barriers to and facilitators of high-quality care
Updates on strategies to integrate palliative care in hematologic malignancy
Evidence-Based Minireview
Wil L. Santivasi,Thomas W. Leblanc
View Articletitled, Updates on strategies to integrate palliative care in hematologic malignancy

Hematologic Management of the Patient with Heavy Menstrual Bleeding

Quantifying menorrhagia and overview of nonsurgical management of heavy menstrual bleeding
Allison P. Wheeler,Celeste O. Hemingway
View Articletitled, Quantifying menorrhagia and overview of nonsurgical management of heavy menstrual bleeding
von Willebrand disease and heavy menstrual bleeding: when and how to test
Juliana Perez Botero
View Articletitled, von Willebrand disease and heavy menstrual bleeding: when and how to test
Heavy menstrual bleeding clinics for adolescents
Maureen Baldwin,Kristina M. Haley,Janice M. Staber
View Articletitled, Heavy menstrual bleeding clinics for adolescents

HIT-and-Run: Challenges in Diagnosis and Management of Heparin-Induced Thrombocytopenia

Practical guide to the diagnosis and management of heparin-induced thrombocytopenia
Jori May,Adam Cuker
View Articletitled, Practical guide to the diagnosis and management of heparin-induced thrombocytopenia
Approaches to management of HIT in complex scenarios, including cardiac surgery
Oluwatayo Adeoye,Guoliang Zheng,Oluwatoyosi A. Onwuemene
View Articletitled, Approaches to management of HIT in complex scenarios, including cardiac surgery
Demystifying autoimmune HIT: what it is, when to test, and how to treat
Marie Scully,William A. Lester
View Articletitled, Demystifying autoimmune HIT: what it is, when to test, and how to treat

Integrating New Therapies into the Management of Classical Heme Disorders

Hypoxia-inducible factor activators: a novel class of oral drugs for the treatment of anemia of chronic kidney disease
Volker H. Haase,Tetsuhiro Tanaka,Mark J. Koury
View Articletitled, Hypoxia-inducible factor activators: a novel class of oral drugs for the treatment of anemia of chronic kidney disease
Luspatercept: a treatment for ineffective erythropoiesis in thalassemia
Khaled M. Musallam,Ali T. Taher
View Articletitled, Luspatercept: a treatment for ineffective erythropoiesis in thalassemia
Givosiran: a targeted treatment for acute intermittent porphyria
Amy K. Dickey,Rebecca K. Leaf
View Articletitled, Givosiran: a targeted treatment for acute intermittent porphyria

Ironing Out the Wrinkles: Managing Iron Overload in Different Clinical Scenarios

Diagnosis and management of hereditary hemochromatosis: lifestyle modification, phlebotomy, and blood donation
Domenico Girelli,Giacomo Marchi,Fabiana Busti
View Articletitled, Diagnosis and management of hereditary hemochromatosis: lifestyle modification, phlebotomy, and blood donation
Iron overload in acquired sideroblastic anemias and MDS: pathophysiology and role of chelation and luspatercept
Norbert Gattermann
View Articletitled, Iron overload in acquired sideroblastic anemias and MDS: pathophysiology and role of chelation and luspatercept
Porphyria cutanea tarda: a unique iron-related disorder
Rebecca K. Leaf,Amy K. Dickey
View Articletitled, Porphyria cutanea tarda: a unique iron-related disorder

It’s a Different World: CLL 2024

Risk-stratification in frontline CLL therapy: standard of care
Eugen Tausch,Christof Schneider,Stephan Stilgenbauer
View Articletitled, Risk-stratification in frontline CLL therapy: standard of care
The evolving frontline management of CLL: are triplets better than doublets? How will we find out?
Kerry A. Rogers,Jennifer A. Woyach
View Articletitled, The evolving frontline management of CLL: are triplets better than doublets? How will we find out?
Relapsed/refractory CLL: the role of allo-SCT, CAR-T, and T-cell engagers
Arnon P. Kater,Tanya Siddiqi
View Articletitled, Relapsed/refractory CLL: the role of allo-SCT, CAR-T, and T-cell engagers

Monoclonal Gammopathies: When the Clone Is More than a Positive Laboratory Finding

MGCS: where do we stand today?
David Iberri,Michaela Liedtke
View Articletitled, MGCS: where do we stand today?
Renal manifestations of MGUS
Frank Bridoux,Samih H. Nasr,Bertrand Arnulf,Nelson Leung,Christophe Sirac,Arnaud Jaccard
View Articletitled, Renal manifestations of MGUS
Neurological manifestations of MGUS
M. Teresa Cibeira,Luis Gerardo Rodríguez-Lobato,Aida Alejaldre,Carlos Fernández de Larrea
View Articletitled, Neurological manifestations of MGUS

Moving the Needle in Hodgkin Lymphoma

Has PD-1 blockade changed the standard of care for cHL?
Thomas M. Kuczmarski,Ryan C. Lynch
View Articletitled, Has PD-1 blockade changed the standard of care for cHL?
When should we use it? The role of brentuximab vedotin in 2024
Joseph G. Schroers-Martin,Ranjana Advani
View Articletitled, When should we use it? The role of brentuximab vedotin in 2024
When to use stem cell transplantation for classical Hodgkin lymphoma
Miguel-Angel Perales,Sairah Ahmed
View Articletitled, When to use stem cell transplantation for classical Hodgkin lymphoma

MPN Practice Pearls: Profiling, Pegylated IFN and Pregnancy

Molecular profiling in MPN: who should have it and why?
Ashlyn Chee,Adam J. Mead
View Articletitled, Molecular profiling in MPN: who should have it and why?
Pegylated interferon: the who, why, and how
Jean-Jacques Kiladjian
View Articletitled, Pegylated interferon: the who, why, and how
Pregnancy: MPN management before, during, and after pregnancy
Joan How,Gabriela Hobbs
View Articletitled, Pregnancy: MPN management before, during, and after pregnancy
What is the optimal strategy for secondary prevention after venous thromboembolism in polycythemia vera?
Evidence-Based Minireview
Helen Ajufo,Jennifer Vaughn
View Articletitled, What is the optimal strategy for secondary prevention after venous thromboembolism in polycythemia vera?

Newly Diagnosed Multiple Myeloma: Many Choices and More Questions

What is the ideal approach—doublet, triplet, or quadruplet(s)?
Shaji K. Kumar
View Articletitled, What is the ideal approach—doublet, triplet, or quadruplet(s)?
Transplant in myeloma: who, when, and why?
Aurore Perrot
View Articletitled, Transplant in myeloma: who, when, and why?
Supportive care in myeloma—when treating the clone alone is not enough
Sonja Zweegman,Niels W. C. J. van de Donk
View Articletitled, Supportive care in myeloma—when treating the clone alone is not enough

Not All Lymphadenopathy is Lymphoma: Lymphoproliferative Diseases of Immune Dysregulation

Identifying Castleman disease from non-clonal inflammatory causes of generalized lymphadenopathy
Sally Nijim,David C. Fajgenbaum
View Articletitled, Identifying Castleman disease from non-clonal inflammatory causes of generalized lymphadenopathy
IgG4-related disease for the hematologist
Luke Y. C. Chen
View Articletitled, IgG4-related disease for the hematologist
EBV and post-transplant lymphoproliferative disorder: a complex relationship
Nader Kim El-Mallawany,Rayne H. Rouce
View Articletitled, EBV and post-transplant lymphoproliferative disorder: a complex relationship

Optimizing Non-Curative Therapies for Sickle Cell Disease

Practical guide for disease-modifying medication management of children and adolescents with sickle cell disease
Joseph Walden,Susan Creary
View Articletitled, Practical guide for disease-modifying medication management of children and adolescents with sickle cell disease
Beyond IV push: alternative methods for management of acute pain in SCD
Melissa Azul,Amanda M. Brandow
View Articletitled, Beyond IV push: alternative methods for management of acute pain in SCD
Novel clinical care models for patients with sickle cell disease
Pablo Bartolucci
View Articletitled, Novel clinical care models for patients with sickle cell disease
Should we use bisphosphonates to treat bone complications in sickle cell disease?
Evidence-Based Minireview
Jahnavi Gollamudi,Oyebimpe Adesina
View Articletitled, Should we use bisphosphonates to treat bone complications in sickle cell disease?

Overcoming Post-Transplant Relapse: How To Win the Battle Royale

Biology of post-transplant relapse: actionable features
Giorgio Orofino,Luca Vago
View Articletitled, Biology of post-transplant relapse: actionable features
Novel conditioning and prophylaxis regimens for relapse prevention
Antonella Mancusi,Loredana Ruggeri,Antonio Pierini
View Articletitled, Novel conditioning and prophylaxis regimens for relapse prevention
Maintenance strategies for relapse prevention and treatment
Emily Geramita,Jing-Zhou Hou,Warren D. Shlomchik,Sawa Ito
View Articletitled, Maintenance strategies for relapse prevention and treatment

Sex Hormones, Contraceptives, and Thrombotic Risk: Where Are We Now?

Estrogen, progestin, and beyond: thrombotic risk and contraceptive choices
Leslie Skeith,Shannon M. Bates
View Articletitled, Estrogen, progestin, and beyond: thrombotic risk and contraceptive choices
Gender-affirming hormone therapy in the transgender patient: influence on thrombotic risk
Hannah King,Thalia Padilla Kelley,Joseph J. Shatzel
View Articletitled, Gender-affirming hormone therapy in the transgender patient: influence on thrombotic risk
Hormone-related thrombosis: duration of anticoagulation, risk of recurrence, and the role of hypercoagulability testing
Luuk J. J. Scheres,Saskia Middeldorp
View Articletitled, Hormone-related thrombosis: duration of anticoagulation, risk of recurrence, and the role of hypercoagulability testing
Inherited thrombophilia and recurrent miscarriage: is there a role for anticoagulation during pregnancy?
Evidence-Based Minireview
Leslie Padrnos,Radhika Gangaraju
View Articletitled, Inherited thrombophilia and recurrent miscarriage: is there a role for anticoagulation during pregnancy?

The Expanding Landscape of Treatment for ITP

Insights on treatment of adult ITP: algorithm for management and role of multimodal therapy
Waleed Ghanima,Adam Cuker,Marc Michel
View Articletitled, Insights on treatment of adult ITP: algorithm for management and role of multimodal therapy
ITP in pregnancy: diagnostics and therapeutics in 2024
Annemarie E. Fogerty
View Articletitled, ITP in pregnancy: diagnostics and therapeutics in 2024
On the horizon: upcoming new agents for the management of ITP
Michele P. Lambert
View Articletitled, On the horizon: upcoming new agents for the management of ITP

Vascular Anomalies, Vascular Malformations, and the Role of the Hematologist

Molecular landscape and classification of vascular anomalies
Emmanuel Seront,Angela Queisser,Laurence M. Boon,Miikka Vikkula
View Articletitled, Molecular landscape and classification of vascular anomalies
Targeted medical therapies for vascular anomalies
Alexandra Borst
View Articletitled, Targeted medical therapies for vascular anomalies
Hemostasis and thrombosis risks and management in vascular anomalies
Shelley E. Crary
View Articletitled, Hemostasis and thrombosis risks and management in vascular anomalies
Potential and emerging therapeutics for HHT
Evidence-Based Minireview
Harish Eswaran,Raj S. Kasthuri
View Articletitled, Potential and emerging therapeutics for HHT

Errata

Platton S, Sivapalaratnam S, Raheja P. Diagnosis and laboratory monitoring of acquired hemophilia A. Hematology Am Soc Hematol Educ Program. 2023;2023(1):11-18.
S Platton,S Sivapalaratnam,P Raheja
View Articletitled, Platton S, Sivapalaratnam S, Raheja P. Diagnosis and laboratory monitoring of acquired hemophilia A. <em>Hematology Am Soc Hematol Educ Program</em>. 2023;2023(1):11-18.
Molina JC, Rotz S. Acute lymphoblastic leukemia in young adults: which up-front treatment? Hematology Am Soc Hematol Educ Program. 2023;2023(1):573-580.
JC Molina,S Rotz
View Articletitled, Molina JC, Rotz S. Acute lymphoblastic leukemia in young adults: which up-front treatment? <em>Hematology Am Soc Hematol Educ Program</em>. 2023;2023(1):573-580.
Anandappa A, Curran E. Challenges to successful outcomes in AYAs with ALL and potential solutions. Hematology Am Soc Hematol Educ Program. 2023;2023(1):587-592.
A Anandappa,E Curran
View Articletitled, Anandappa A, Curran E. Challenges to successful outcomes in AYAs with ALL and potential solutions. <em>Hematology Am Soc Hematol Educ Program</em>. 2023;2023(1):587-592.
All Issues
Targeted medical therapies for vascular anomalies
T-cell–based therapies for treating relapsed or refractory mantle cell lymphoma
Transplant in ALL: who, when, and how?
Ph− ALL: immunotherapy in upfront treatment
Ph+ ALL: new approaches for upfront therapy
  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal